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Macrolides are used to treat various inflammatory diseases owing to their immunomodulatory
properties; however, little is known about their precise mechanism of action. In this study, we
investigated the functional significance of the expansion of myeloid-derived suppressor cell
(MDSC)-like CD11b+Gr-1+ cells in response to the macrolide antibiotic clarithromycin (CAM) in
mouse models of shock and post-influenza pneumococcal pneumonia as well as in humans.
Intraperitoneal administration of CAM markedly expanded splenic and lung CD11b+Gr-1+ cell
populations in naïve mice. Notably, CAM pretreatment enhanced survival in a mouse model
of lipopolysaccharide (LPS)-induced shock. In addition, adoptive transfer of CAM-treated
CD11b+Gr-1+ cells protected mice against LPS-induced lethality via increased IL-10 expres-
sion. CAM also improved survival in post-influenza, CAM-resistant pneumococcal pneumonia,
with improved lung pathology as well as decreased interferon (IFN)-γ and increased IL-10 lev-
els. Adoptive transfer of CAM-treated CD11b+Gr-1+ cells protected mice from post-influenza
pneumococcal pneumonia. Further analysis revealed that the CAM-induced CD11b+Gr-1+ cell
expansion was dependent on STAT3-mediated Bv8 production and may be facilitated by the
presence of gut commensal microbiota. Lastly, an analysis of peripheral blood obtained from
healthy volunteers following oral CAM administration showed a trend toward the expansion of
human MDSC-like cells (Lineage−HLA-DR−CD11b+CD33+) with increased arginase 1 mRNA
expression. Thus, CAM promoted the expansion of a unique population of immunosuppressive
CD11b+Gr-1+ cells essential for the immunomodulatory properties of macrolides.
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Author summary
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of anti-
inflammatory myeloid progenitors that expand in response to acute and chronic inflam-
mation as well as in various diseases, such as autoimmune diseases and cancer. The
macrolide antibiotic clarithromycin has immunomodulatory effects in various inflamma-
tory diseases, distinct from its antimicrobial effects, but the mechanism underlying these
effects is unknown. The present study demonstrates that clarithromycin treatment
induces a marked expansion of CD11b+Gr-1+ MDSC-like cells in the spleen and lungs,
sufficient to protect mice from LPS-induced lethality and clarithromycin-resistant bacte-
rial pneumonia via increased IL-10 and decreased IFN-γ levels. Clarithromycin-induced
CD11b+Gr-1+ cell expansion was dependent on STAT3-mediated Bv8 production. More-
over, expansion of the immunosuppressive MDSC-like cell population was observed fol-
lowing clarithromycin treatment in humans. Collectively, these results suggest that the
immunomodulatory effects of clarithromycin can be attributed to the induction of
CD11b+Gr-1+ MDSC-like cells via the STAT3/Bv8 axis.
Introduction
Macrolides have immunomodulatory properties in addition to their antibacterial effects [1, 2].
Indeed, previous clinical trials have shown that macrolides exhibit clinical benefits for various
pulmonary diseases, including diffuse panbronchiolitis [3], chronic obstructive pulmonary
disease [4], acute respiratory distress syndrome [5], cystic fibrosis [6], and non-cystic fibrosis
bronchiectasis [7]. However, the precise mechanism underlying their favorable immunomod-
ulatory effects remains largely unknown.
Previous studies of macrolides have focused on their in vitro effects on isolated cells,
such as immune cells, epithelial cells, endothelial cells, and fibroblasts [8]. In particular,
macrolides inhibit the production of pro-inflammatory cytokines [9]; however, the effects
of macrolides on specific immune cell populations have not been examined. We hypothe-
sized that the immunomodulatory properties of macrolides are physiological in origin, as
they exhibit globally beneficial effects for various inflammatory diseases with different
pathogenesis.
Myeloid-derived suppressor cells (MDSCs), a heterogeneous population of myeloid pro-
genitors, are expanded in various diseases, including cancer, bacterial and parasitic infections,
acute and chronic inflammation, sepsis, transplantation, and autoimmunity, and can potently
suppress T-cell responses [10–12]. In mice, MDSCs express both CD11b and Gr-1, whereas
human MDSCs mainly express Lineage−HLA-DR−CD11b+CD33+ or CD11b+CD14−CD33+,
but lack markers homologous to mouse Gr-1 [10, 11]. Here, we present evidence that clarith-
romycin (CAM), a 14-membered macrolide, expands the immunosuppressive CD11b+Gr-1+
cell population to ameliorate lipopolysaccharide (LPS)-induced shock and post-influenza
pneumococcal pneumonia in mice. We also demonstrate a CAM-induced expansion of the
human Lineage−HLA-DR−CD11b+CD33+ cell population in healthy volunteers similar to that
observed for CD11b+Gr-1+ cells in mice. Our findings shed new light on the novel immuno-
modulatory mechanism of macrolides and will contribute to the development of novel
approaches to treat inflammatory diseases.
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Results
Clarithromycin expands the CD11b+Gr-1+ cell population
We first examined whether macrolides, in this case CAM, could modulate immune cell popula-
tions in wild-type (WT) mice. Naive WT mice were intraperitoneally administered CAM daily
for 3 days, and single-cell suspensions prepared from the spleen and lungs were analyzed by flow
cytometry on the day after the last injection. We did not detect significant differences in the
numbers of NK1.1+, B220+, CD4+, and CD8+ lymphocytes in both the spleen and lungs between
vehicle- and CAM-treated mice (Fig 1A and 1B). Conversely, CAM administration markedly
expanded the splenic and lung CD11b+Gr-1+ cell population in naive mice (Fig 1C–1E). This
significant increase in CD11b+Gr-1+ cell number was also observed after oral administration of
CAM for 2 weeks (Fig 1F and 1G). Next, we intraperitoneally injected CAM at various doses
daily for three consecutive days and analyzed cell expansion 24 h after the last injection. As
expected, CAM administration increased the CD11b+Gr-1+ cell population in a dose-dependent
and time-dependent manner (S1 Fig). We further analyzed two populations of Gr-1+ cells, i.e.,
the Ly-6G+ and Ly-6C+ cell populations. Indeed, CAM-treated CD11b+Gr1+ cells were divided
into two subsets: CD11b+Ly-6G−Ly-6C+ cells and CD11b+Ly-6G+Ly-6Clow cells (Fig 1H). A
cytospin analysis revealed that CD11b+Ly-6G−Ly-6C+ cells displayed a monocytic morphology
(Fig 1I), whereas CD11b+Ly-6G+Ly-6Clow cells showed a granulocytic morphology (Fig 1J).
The lungs were harvested from mice administered CAM daily for three consecutive days 24
h after the last CAM injection and stained with Gr-1 antibody. Of note, only Gr-1+ immunos-
taining was used because a previous flow cytometry analysis revealed that nearly all Gr-1+ cells
in the lungs after CAM treatment were CD11b+ cells (Fig 1D). Interestingly, Gr-1+ cells
increased markedly after CAM treatment and were mainly located in the extravascular space
of the lungs (i.e., the lung parenchyma or interstitium) (S2 Fig).
CAM-treated CD11b+Gr-1+ cell population exhibits immunomodulatory
properties
To further characterize the CAM-treated CD11b+Gr-1+ cell phenotype, we performed a
microarray analysis with sorted splenic CD11b+Gr-1+ cells obtained from vehicle- and CAM-
treated mice. We detected a 310-fold increase in the expression of arginase-1 expression,
which is a key enzyme inhibiting T cell proliferation and an MDSC marker (Fig 2A). We con-
firmed that both intraperitoneal injection and oral administration of CAM induced arginase-1
mRNA expression in splenic CD11b+Gr-1+ cells (S3 Fig). We further measured arginase ac-
tivity in the spleen and arginase-1 expression in the lungs. High arginase activity was detected
in CAM-treated CD11b+Gr-1+ cells, whereas no activity was detected in vehicle-treated
CD11b+Gr-1+ cells (Fig 2B). In addition, immunostaining analysis confirmed that Gr-1+ cells
produce arginase-1 in the lungs of CAM-treated mice (Fig 2C).
We next measured the concentration of splenic nitric oxide (NO), a crucial parameter for
MDSC biology and identification [13]. The NO concentration was significantly higher in the
spleen of CAM-treated mice than in that of vehicle-treated mice (Fig 2D).
To further investigate the function of CAM-treated CD11b+Gr-1+ cells in comparison with
neutrophils and monocytes/macrophages, elastase activity, MPO activity, and phagocytic
activity were measured (S4 Fig). Elastase activity in CAM-treated CD11b+Gr-1+ cells was
lower than that in any other group (vehicle-treated CD11b+Gr-1+ cells [mainly steady-state
non-activated neutrophils and monocytes/macrophages], LPS-treated CD11b+Gr-1+ cells
(mainly activated neutrophils and monocytes/macrophages), thioglycolate-elicited sterile peri-
tonitis-induced activated neutrophils, and isolated peripheral non-activated neutrophils) (S4A
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Fig), consistent with the notion that elastase activity in MDSCs is lower than that in neutro-
phils. MPO activity in CAM-treated CD11b+Gr-1+ cells was greater than that in vehicle-
treated CD11b+Gr-1+ cells and in peripheral neutrophils, which appeared to be non-activated
steady-state neutrophils or monocytes/macrophages. However, it was lower than that in LPS-
treated CD11b+Gr-1+ cells (activated neutrophils and monocytes/macrophages) and thiogly-
colate-elicited sterile peritonitis-induced activated neutrophils (S4B Fig). In addition, phago-
cytic activity in CAM-treated CD11b+Gr-1+ cells was lower than that in any other group (S4C
Fig), supporting the notion that CAM-treated CD11b+Gr-1+ cells are not neutrophils or
monocytes/macrophages, but MDSC-like cells.
To verify that CAM-treated CD11b+Gr-1+ cells suppressed T cell activity, the minimal
functional characteristic necessary to identify cells as MDSCs [13], we performed carboxy-
fluorescein succinimidyl ester (CFSE) T cell proliferation assays. The histogram of CD3+ T
cells co-cultured with CAM-treated CD11b+Gr-1+ cells shifted to the right along the X-axis
when compared to that for the vehicle-treated CD11b+Gr-1+ cells, but the degree of the shift
was modest. These results indicate that CAM-treated CD11b+Gr-1+ cells might hinder CD3+
T cell proliferation (S5 Fig).
We next examined the CAM-treated CD11b+Gr-1+ cells for the presence of various surface
markers expressed on MDSCs and/or myeloid cells, including CD244 [14], CTLA-4 [15], PD-
1 [16], PD-L1 [17], CXCR2 [11], CXCR4 [11], CD80 [11], CD115 [11], and CX3CR1 [18].
There were no dramatic differences in the expression of these markers, but CD244 and CTLA-
4 expression tended to be slightly higher in CAM-treated CD11b+Gr-1+ cells than in vehicle-
treated CD11b+Gr-1+ cells (S6 Fig). Because CD244 is specifically expressed on granulocytic
MDSCs [14], we evaluated CD244 in CD11b+Ly-6G+ cells. We confirmed high CD244 expres-
sion levels in CAM-treated CD11b+Ly6G+ cells (Fig 2E).
To further investigate the functions of these cell populations in vitro, bone marrow-derived
macrophages (BMDMs) were co-cultured with CAM- or vehicle-treated CD11b+Gr-1+ cells
stimulated with LPS (i.e., with cell–cell contact), and cytokine secretion was assessed 12 h later.
Notably, CAM-treated CD11b+Gr-1+ cells suppressed pro-inflammatory cytokine production
(TNF-α and IFN-γ) and increased anti-inflammatory IL-10 levels (Fig 2F–2H). Collectively,
these in vitro results indicate that CAM-treated CD11b+Gr-1+ cells potentiate immunomodu-
latory properties related to cytokine production.
Potency of other macrolides in CD11b+Gr-1+ cell expansion
Previous studies have suggested that 14- and 15-membered ring, but not 16-membered ring
macrolides have immunomodulatory properties [19, 20]; thus, we evaluated the immunomod-
ulatory properties of various macrolides by assessing CD11b+Gr-1+ cell expansion. Interest-
ingly, CAM (14-membered ring) and azithromycin (15-membered ring), but not josamycin
Fig 1. Clarithromycin expands CD11b+Gr-1+ cells in naive mice. (A and B) Quantification of major lymphocyte populations,
including B220+, NK1.1+, CD4+, and CD8+ cells, in the lymphocyte gate in the spleen (A) and lungs (B) sorted from mice that
were intraperitoneally treated with vehicle or clarithromycin (CAM; 100 mg/day) daily for three consecutive days. Data are
expressed as the mean ± SEM (n = 4 per group). (C and D) Representative two-parameter dot plots of CD11b+Gr-1+ cells in the
spleen (C) and lungs (D) sorted from mice intraperitoneally treated with vehicle or CAM daily for three consecutive days. (E)
Quantification of CD11b+Gr-1+ cells in the spleen and lungs sorted from intraperitoneally vehicle- and CAM-treated mice
(n = 6–7 per group). p< 0.001 by the Mann–Whitney U-test. (F and G) Representative two-parameter dot plots of
CD11b+Gr-1+ cells in the spleen (F) and lungs (G) sorted from mice intragastrically administered vehicle or CAM (100 mg/day)
daily for 14 consecutive days (n = 4 per group). (H) CAM-treated CD11b+Gr-1+ cells in the spleen were divided into two groups:
CD11b+Ly-6G−Ly-6C+ cells and CD11b+Ly-6G+Ly-6Clow cells (n = 4 per group). (I and J) Representative cytospin images of (I)
CD11b+Ly-6G−Ly-6C+ cells (monocytic MDSC-like cells) and (J) CD11b+Ly-6G+Ly-6Clow cells (granulocytic MDSC-like cells)
(n = 4 per group).
https://doi.org/10.1371/journal.ppat.1006955.g001
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Fig 2. CAM-treated CD11b+Gr-1+ cells exhibit an immunosuppressive phenotype. (A) Top 25 upregulated and downregulated genes
determined by a microarray analysis in splenic CD11b+Gr-1+ cells sorted from vehicle- and CAM-treated mice. Stxbp6 (chromosome
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(JOS) (16-membered ring), increased the percentage and number of splenic and lung
CD11b+Gr-1+ cells (S7 Fig). Because 14- and 15-, but not 16-membered macrolide antibiotics
can decrease pro-inflammatory cytokine and chemokine secretion, these results suggest that
the extent of macrolide-induced CD11b+Gr-1+ cell expansion is an indicator of their immuno-
modulatory effects.
CAM improves survival in a mouse model of LPS-endotoxin shock via
CD11b+Gr-1+cells
To examine the immunomodulatory properties of CAM-treated CD11b+Gr-1+ cells in vivo,
mice were subjected to LPS-endotoxin shock. Pretreatment with CAM significantly increased
survival (Fig 3A). Moreover, TNF-α and IFN-γ serum levels were significantly lower in CAM-
treated mice 12 h after LPS injection, and IL-10 levels were significantly higher than those in
vehicle-treated counterparts (Fig 3B–3D). A flow cytometry analysis revealed that CAM accel-
erated the LPS-dependent expansion of CD11b+Gr-1+ cells in both the spleen and lungs (Fig
3E and 3F). The numbers of CD11b+Gr-1+ cells in the spleen and lungs were slightly, but sig-
nificantly higher in CAM-treated mice than in vehicle-treated mice (Fig 3G).
To investigate the role of the CD11b+Gr-1+ cell population in the LPS-shock model, we
attempted to deplete CD11b+Gr-1+ cells. The experimental schema for the analysis summarized
in Fig 3H and 3I is shown in S8 Fig. Because>85% of splenic and lung Gr-1+ cells in CAM-
treated LPS-shock mice were CD11b+ (Fig 3E and 3F), we used an anti-Gr-1 (including Ly-6G
and Ly-6C) antibody to deplete this cell population. The improved survival observed for CAM
treatment in the LPS-shock model was reversed by Gr-1+ cell depletion at 24 h before LPS treat-
ment (Fig 3H). In addition, we obtained similar results when the Gr-1+ cell population was
depleted 1 h before the first CAM treatment (i.e., from the beginning of CAM treatment) (Fig 3I).
These results indicate that the CAM-treated Gr-1 population has protective effects in this model.
Next, we adoptively transferred CD11b+Gr-1+ cells isolated from CAM- or vehicle-treated donors
to LPS-challenged recipient mice. Adoptive transfer of CAM-treated CD11b+Gr-1+ cells protected
mice from LPS-induced lethality, as compared to vehicle-treated CD11b+Gr-1+ cells (Fig 3J)
and PBS control injections (S9 Fig), and was associated with decreased TNF-α and IFN-γ and
increased IL-10 serum levels (Fig 3K–3M). Collectively, these results indicated that CAM amelio-
rates LPS-induced lethality via CAM-treated CD11b+Gr-1+ cells.
IL-10 production in CD11b+Gr-1+ cells protects against LPS-induced
endotoxin shock
Because CAM-treated CD11b+Gr-1+ cells potentiated anti-inflammatory IL-10 secretion in
response to LPS stimulation (Fig 2F), we hypothesized that IL-10 production in CD11b+Gr-1+
cells contributed to the beneficial effects on LPS-induced shock. To evaluate our hypothesis,
we adoptively transferred CAM-treated CD11b+Gr-1+ cells from WT and IL-10 knockout
(Il10-/-) donors into syngeneic WT recipients. Notably, WT CD11b+Gr-1+ cell grafts improved
12:45956210–46175345). Stxbp6 (chromosome 12:45953470–45956090). Results are presented as fold changes relative to the expression
levels of each gene in vehicle-treated CD11b+Gr-1+ cells. (B) Arginase activity in the spleen of vehicle- and CAM-treated mice (n = 4 per
group). N.D., not detected. (C) Immunofluorescence staining of Gr-1 and arginase-1 in the lungs of mice treated with CAM daily for
three consecutive days (n = 4 per group). Scale bar, 200 μm. (D) The concentration of nitric oxide (NO) in spleen extracts of vehicle- and
CAM-treated mice (n = 4 per group) p< 0.001 by the Mann–Whitney U-test. (E) Expression of the surface marker CD244 on splenic
CD11b+Ly-6G+ cells determined by flow cytometry (n = 4 per group). (F–H) Cytokine profile of the culture supernatant from bone
marrow-derived macrophages (BMDMs) with or without equal numbers of vehicle-treated or CAM-treated CD11b+Gr-1+ cells (5 × 105
cells) in the spleen: TNF-α (F), IFN-γ (G), and IL-10 (H). Representative data for three independent experiments are shown. Data are
expressed as the mean ± SEM. p< 0.001 by a one-way ANOVA with Tukey’s multiple comparison tests.
https://doi.org/10.1371/journal.ppat.1006955.g002
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Fig 3. CAM ameliorates LPS-endotoxin shock via the essential contribution of CD11b+Gr-1+ cells. (A) Survival rate for LPS (50
mg/kg)-endotoxin shock in mice pretreated with vehicle or CAM (100 mg/day) daily for three consecutive days (n = 36 per group).
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survival in the LPS-induced shock model, whereas those from Il10-/- donors failed to convey
these effects (Fig 4A), indicating that IL-10 production from CAM-treated CD11b+Gr-1+ cells
contributed to the protective effects of macrolides in LPS-induced endotoxin shock. To con-
firm these effects in vitro, we measured supernatant cytokine levels in co-cultures of BMDMs
and CAM-treated WT or Il10-/- CD11b+Gr-1+ cells 12 h after LPS stimulation. As expected,
the TNF-α and IFN-γ levels were significantly higher in cells co-cultured with Il10-/- cells
than in those from WT counterparts (Fig 4B and 4C), indicating that the decreased pro-
inflammatory cytokine production by CAM-treated CD11b+Gr-1+ cells was at least partially
IL-10-dependent.
We further investigated the role of IL-10 in expansion of the CAM-treated CD11b+Gr1+
cell population. CAM still expanded CD11b+Gr-1+ cells in Il10-/- mice, suggesting that the
major expansion mechanism of CD11b+Gr1+ cells by CAM is not related to IL-10 (S10 Fig).
CAM improves the survival of mice with post-influenza pneumococcal
pneumonia via CD11b+Gr-1+cells
We examined the immunomodulatory effects of CAM-treated CD11b+Gr-1+ cells in a mouse
model of post-influenza pneumococcal pneumonia. In particular, we used a clinically isolated
strain of Streptococcus pneumoniae (serotype 3) that harbors penicillin and macrolide resis-
tance genes, although the strain was classified as a penicillin-intermediate resistant S. pneumo-
niae (PISP), as described in the Materials and Methods section and S1 Table. CAM treatment
significantly improved survival when compared to that of vehicle- or ampicillin (ABPC)-
treated mice (Fig 5A), whereas JOS treatment did not improve survival (S11 Fig). Interestingly,
both CAM and ABPC significantly reduced total cell counts in bronchoalveolar lavage fluid
(BALF) as compared to those in vehicle-treated mice (Fig 5B), as well as the bacterial load in
lungs 18 h after infection (Fig 5C). Blood cultures showed lower bacterial loads in CAM-
treated mice than in vehicle- and ABPC-treated mice, but the differences were not significant
(Fig 5D). Moreover, a histopathological examination of the lungs 18 h after pneumococcal
infection indicated that both CAM and ABPC ameliorated white blood cell recruitment
(mainly neutrophils), alveolar wall thickening, and edema when compared to those of vehicle-
treated mice (Fig 5E). Furthermore, IFN-γ levels were significantly suppressed in the BALF
and serum in CAM-treated mice as compared to vehicle-treated and ABPC-treated mice,
respectively, whereas IL-10 was markedly increased in both the BALF and serum of CAM-
treated mice (Fig 5F–5I). Similarly, adoptive transfer of splenic CD11b+Gr-1+cells into mice
with post-influenza pneumococcal pneumonia immediately after pneumococcal inoculation
p = 0.0009 by the log-rank test. (B–D) Cytokine profiles in serum 12 h after LPS challenge in vehicle- or CAM-treated mice: TNF-α
(B), IFN-γ (C), and IL-10 (D). (n = 5–6 per group). Data are represented as the mean ± SEM. p< 0.01. p< 0.001 by the
Mann–Whitney U-tests. (E and F) Representative two-parameter dot plots of CD11b+Gr-1+ cells in the spleen (E) and lungs (F) of
mice intraperitoneally treated with vehicle or CAM (100 mg/day) daily for three consecutive days, followed by intraperitoneal
injection with PBS or LPS (50 mg/kg) (n = 4 per group). (G) Quantification of CD11b+Gr-1+ cells in the spleen and lungs sorted
from intraperitoneally vehicle- and CAM-treated (once a day for 3 days), followed by intraperitoneally LPS-treated mice (n = 4 per
group). p< 0.05, p< 0.01 by Mann–Whitney U-tests. (H) Survival rate for LPS-endotoxin shock in vehicle- and CAM-injected
mice pretreated with either anti-Gr-1 antibody (250 μg/mouse) or control IgG (n = 20–21 per group) 24 h before LPS challenge.
p = 0.0128 by the log-rank test. (I) Survival rate for LPS-endotoxin shock in vehicle- and CAM-injected mice pretreated with either
anti-Gr-1 antibody (250 μg/mouse) or control IgG (n = 25–26 per group) 1 h before initiation of CAM treatment (i.e., 73 h before
LPS challenge). Combined data for two independent experiments are shown. p< 0.001 by the log-rank test. (J) Adoptive transfer
of CAM-treated CD11b+Gr-1+ cells improved the survival rate in LPS endotoxin shock (n = 24 per group). p = 0.0023 by the log-
rank test. (K-M) TNF-α (K), IFN-γ (L), and IL-10 (M) levels in serum at 12 h after intraperitoneal LPS injection (n = 5–6 per
group). Data are presented as the mean ± SEM. p< 0.05. p< 0.01. p< 0.001 by the Mann–Whitney U-tests.
https://doi.org/10.1371/journal.ppat.1006955.g003
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revealed that CAM-treated CD11b+Gr-1+ cells prolonged the survival of recipient mice when
compared to ABPC- or vehicle-treated counterparts (Fig 5J).
Fig 4. IL-10 production by CAM-treated CD11b+Gr-1+ cells is beneficial for LPS endotoxin shock. (A) CAM-
treated or vehicle-treated CD11b+Gr-1+ cells in the spleen sorted from either IL-10 knockout or WT mice were
adoptively transferred into LPS endotoxin-treated recipients (n = 25–30 per group). Combined data for two
independent experiments are shown. p = 0.0137 by the log-rank test. (B and C) Levels of the pro-inflammatory
cytokines TNF-α (B) and IFN-γ (C) in the supernatant of WT BMDMs co-cultured with either WT or IL-10 knockout
CD11b+Gr-1+ cells in the spleen treated with vehicle or CAM (n = 3 per group). Data are presented as the
mean ± SEM. p< 0.01 by a one-way ANOVA with Tukey’s multiple comparison tests.
https://doi.org/10.1371/journal.ppat.1006955.g004
Clarithromycin expands CD11b+Gr-1+ MDSC-like cells
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006955 April 5, 2018 10 / 30
Previous studies of post-influenza pneumococcal pneumonia have reported that IFN-γ pro-
duction is detrimental to secondary bacterial infection [21, 22]; thus, because our results
showed that CAM and CAM-treated CD11b+Gr-1+ cells suppress IFN-γ production in post-
Fig 5. CAM improves survival in post-influenza pneumococcal pneumonia via an essential contribution of CD11b+Gr-1+ cells. (A) Survival rate of post-influenza
pneumococcal pneumonia mice treated with vehicle, ampicillin (ABPC) (100 mg/kg), or clarithromycin (CAM) (100 mg/kg) (n = 37 per group). p< 0.05,
p< 0.001 by the log-rank test. (B) Cell counts in bronchoalveolar lavage fluid (BALF) obtained from mice with post-influenza pneumococcal pneumonia treated
with vehicle, ABPC (100 mg/kg), or CAM (100 mg/kg) (n = 7–8 per group). Data are presented as the mean ± SEM. p< 0.05. p< 0.01, p< 0.001 by a two-way
ANOVA with Tukey’s multiple comparison tests. (C and D) Bacterial load in the lungs (C) and blood (D) of post-influenza pneumococcal pneumonia mice treated
with vehicle, ABPC (100 mg/kg), or CAM (100 mg/kg) at 18 and 36 h after pneumococcal infection (n = 15–16 per group). Data are presented as the mean ± SEM.
p< 0.05 by a two-way ANOVA with Tukey’s multiple comparison tests. (E) Lung H&E staining at 48 h after pneumococcal infection. Representative data for 5 mice
per group are shown. Scale bar, 100 μm. (F–I) Levels of IFN-γ (F) and IL-10 (G) in BALF were measured by ELISA. The levels of IFN-γ (H) and IL-10 (I) in serum were
measured by ELISA (n = 7–8 per group). Data are presented as the mean ± SEM. p< 0.05. p< 0.01. p< 0.001 by a two-way ANOVA with Tukey’s multiple
comparison tests. (J) Survival rate of mice following adoptive transfer of CD11b+Gr-1+ cells treated with vehicle, ABPC (100 mg/kg), or CAM (100 mg/kg) in post-
influenza pneumococcal pneumonia mice (n = 34 per group). Combined data for two independent experiments are shown. p< 0.05. p< 0.01 by the log-rank test.
(K) Survival rate of vehicle-, ABPC-, and CAM-treated mice intranasally inoculated with recombinant IFN-γ (16 μg/kg) or PBS at 30 min and 24 h after pneumococcal
infection (n = 20 per group). (L) Survival rate of vehicle- or CAM-treated WT and Ifng-/- mice with post-influenza pneumococcal pneumonia (n = 7–16 per group).
https://doi.org/10.1371/journal.ppat.1006955.g005
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influenza pneumococcal pneumonia, we hypothesized that IFN-γ might have a detrimental
effect on survival in our model mice. Indeed, CAM-mediated prolonged survival was partially
reversed by intranasal administration of recombinant IFN-γ (Fig 5K). To further investigate
the roles of IFN-γ in CAM-treated CD11b+Gr-1+ cells, IFN-γ deficient (Ifng-/-) and WT mice
were subjected to post-influenza pneumococcal pneumonia. We first confirmed better survival
in vehicle-treated Ifng-/- mice than in vehicle-treated WT mice (Fig 5L), consistent with previ-
ous results showing that Ifng-/- mice are resistant to post-influenza pneumococcal pneumonia
[22]. We also observed slightly higher survival in CAM-treated Ifng-/- mice than in vehicle-
treated Ifng-/- mice and CAM-treated WT mice (Fig 5L), suggesting that the protective effects
of CAM in this model depend, at least in part, on suppression of IFN-γ production. Collec-
tively, these data demonstrate that CAM improves the overall survival of mice with post-influ-
enza pneumococcal pneumonia, at least in part via suppression of IFN-γ production by CAM-
treated CD11b+Gr-1+ cells.
Previous studies have indicated that type I IFN is also detrimental in a post-influenza pneu-
mococcal pneumonia model using interferon-α/β receptor (IFNAR) knockout (Ifnar1-/-) mice
[23]. To investigate the role of type I IFN in CAM-treated CD11b+Gr-1+ cells, Ifnar1-/- mice
and WT mice were subjected to post-influenza pneumococcal pneumonia. We did not observe
a significant difference between WT mice and Ifnar1-/- mice. In addition, CAM did not signifi-
cantly improve survival in Ifnar1-/- mice, but it resulted in a slight improvement in survival in
Ifnar1-/- mice (S12 Fig). These results may be explained by the strong virulence of influenza in
Ifnar1-/- mice. Accordingly, we could not determine whether the protective effects of CAM in
post-influenza pneumococcal pneumonia are independent or partially dependent on type I
IFN, and additional studies with larger sample sizes are needed.
CAM expanded CD11b+Gr-1+ cells via the STAT3-Bv8 axis
We next explored the mechanism underlying CAM-induced CD11b+Gr-1+ cell expansion,
and initially focused on effectors known to induce the differentiation and proliferation of
CD11b+Gr-1+ cells, including IL-17, CCL2, CXCR4, and toll-like receptor (TLR)/MyD88 sig-
naling [10]. Thus, we examined CAM-mediated CD11b+Gr-1+ cell expansion in Il17a-/-, Ccl2-/-,
and Myd88-/- mice, as well as WT mice treated with a CXCR4 antagonist (AMD3100). However,
no differences were observed between these mice and WT controls (S13 Fig), indicating that IL-
17, CCL2, CXCR4, and TLR/MyD88 signaling pathways are not involved in this process.
The prokineticin family member Bv8 (also known as prokineticin 2 [Prok2]) was previously
reported to induce CD11b+Gr-1+ cells in an autocrine and paracrine STAT3-dependent man-
ner [24]. Notably, our microarray data identified that Bv8 (Prok2) was highly expressed
(12.3-fold higher relative to WT mice) in splenic CD11b+Gr-1+ cells obtained from CAM-
treated mice (Fig 2A). A protein analysis of splenic cells after CAM treatment revealed higher
Bv8 expression than that in vehicle-treated mice (Fig 6A), as well as increased phosphorylated
(p)-STAT3 (Fig 6B). To investigate the role of Bv8 in CAM-induced CD11b+Gr-1+ cell induc-
tion, mice were administered an anti-Bv8 antibody at 4 days and 1 day before, and then dur-
ing, the CAM treatment period (three consecutive days). Notably, treatment with the anti-Bv8
antibody reduced the percentage of CD11b+Gr-1+ cells in both the spleen (16.5% vs. 6.59%;
60.1% reduction) (Fig 6C) and lungs (14.3% vs. 8.04%; 43.8% reduction) (Fig 6D). Because
Bv8 and STAT3 form a feed-forward loop that promotes CD11b+Gr-1+ myeloid cell prolifera-
tion [24], we investigated this as a potential induction mechanism in Stat3flox/flox/Mx1-Cre
(Stat3ΔMx1) mice. As predicted, the CAM-treated CD11b+Gr-1+ cell populations in the spleen
and lungs were reduced in Stat3ΔMx1 mice (Fig 6E and 6F). Consistently, Bv8 gene expression
was significantly reduced in splenic CD11b+Gr-1+ cells isolated from CAM-treated Stat3ΔMx1
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mice when compared to expression in Stat3flox/flox control mice (Fig 6G). Taken together, these
results indicate that STAT3-Bv8 signaling facilitates the CAM-mediated expansion of the
CD11b+Gr-1+ cell population.
Gut commensal microbiota may contribute to CAM-induced CD11b+Gr-1+
cell expansion
Macrolide administration causes substantial changes in the composition of the gut microbiota
[25]. Accordingly, we hypothesized that the modulation of the gut microbiota by CAM might
contribute to the expansion of CD11b+Gr-1+ cells. To investigate this hypothesis, germ-free
mice and specific pathogen-free (SPF) mice were administered CAM daily for three consecu-
tive days, and the CD11b+Gr-1+ cell populations were quantified the day after the last injec-
tion. The baseline CD11b+Gr-1+ cell population in untreated germ-free mice was significantly
lower than that in untreated SPF mice (S14 Fig), suggesting that the resident CD11b+Gr-1+
cell population is influenced by the gut commensal microbiota. Moreover, expansion of the
CD11b+Gr-1+ cell population by CAM was also observed in both germ-free mice and SPF
mice; however, the relative expansion of splenic and lung CD11b+Gr-1+ cells was significantly
lower in CAM-treated germ-free mice than in SPF counterparts, suggesting that commensal
gut microbiota enhance CD11b+Gr-1+ cell population expansion in response to CAM treat-
ment (S14 Fig).
CAM modulates the immunosuppressive properties of
Lineage−HLA-DR−CD11b+CD33+ cells in humans
To determine whether the immunosuppressive MDSC-like population also exhibits CAM-
induced expansion in humans, six healthy volunteers were administered 800 mg of CAM daily
for 7 days and relative changes in the Lineage−HLA-DR−CD11b+CD33+ MDSC population
were examined in peripheral blood by flow cytometry (Fig 7A). Although the Lineage−H-
LA-DR−CD11b+CD33+ cell population appeared to increase following CAM treatment, the
difference was not significant (p = 0.0699) (Fig 7B); however, arginase-1 gene expression was
markedly elevated in these cells after 7 days of CAM treatment compared to the baseline con-
trol measurements (Fig 7C). These results suggest that human Lineage−HLA-DR−CD11b+CD33+
MDSCs were polarized to a more immunosuppressive phenotype in response to CAM treatment.
Discussion
In this study, we demonstrated that CAM stimulates the expansion of the immunosuppressive
CD11b+Gr-1+ cell population to enhance survival in a LPS-induced shock and post-influenza
pneumococcal pneumonia mouse model, in a STAT3/Bv8 axis-dependent manner. We also
showed that human Lineage−HLA-DR−CD11b+CD33+ cells correspond to the CD11b+Gr-1+
Fig 6. CAM expands the CD11b+Gr-1+ cell population via the STAT3-Bv8 axis. (A and B) Representative immunoblotting of
Bv8 (A) and phosphorylated (p)-STAT3 (B). Beta-actin and total (t) STAT3 were used as loading controls. Relative band intensities
ware quantified by densitometry. (C and D) Representative two-parameter dot plots of CD11b+Gr-1+ cells in the spleen (C) and
lungs (D) sorted from mice intraperitoneally treated with vehicle or CAM (100 mg/day) daily for three consecutive days. Mice were
intraperitoneally injected with an anti-Bv8 antibody (5 mg/kg) or control IgG at 4 days and 1 day before CAM treatment and daily
for three consecutive days during CAM treatment (n = 4 per group). (E and F) Representative two-parameter dot plots of
CD11b+Gr-1+ cells in the spleen (E) and lungs (F) sorted from poly(I:C)-treated Stat3flox/flox/Mx1-Cre (Stat3ΔMx1) mice and control
Stat3flox/flox mice that were intraperitoneally treated with vehicle or CAM (100 mg/day) daily for three consecutive days (n = 4 per
group). (G) Bv8 (Prok2) mRNA expression in CD11b+Gr-1+ cells sorted from Stat3ΔMx1 mice and control Stat3flox/flox mice (n = 4
per group). Data are presented as the mean ± SEM. p< 0.001 by the Mann–Whitney U-test.
https://doi.org/10.1371/journal.ppat.1006955.g006
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population in mice, as they both exhibited a significant increase in arginase-1 mRNA expres-
sion levels following CAM treatment.
Increasing evidence suggests that macrolides have immunomodulatory properties, beyond
their antibacterial effects [1, 2]; however, the overuse of these drugs for this purpose is criti-
cized because the mechanism of action is unclear [26]. Therefore, the elucidation of their exact
immunomodulatory effects is needed. Numerous in vitro studies have demonstrated that
macrolides modulate the release of humoral factors from immune, epithelial, and other
Fig 7. Immunosuppressive properties of human Lineage-HLA-DR-CD11b+CD33+ cells expanded by CAM
treatment. (A) Representative two-parameter dot plots of Lineage-HLA-DR-CD11b+CD33+ cells of healthy volunteers
evaluated by flow cytometry (n = 6). PI, propidium iodide. (B) Percentage of Lineage-HLA-DR-CD11b+CD33+ cells
before and 7 days after oral treatment with CAM (800 mg/day). Data were analyzed by the Wilcoxon matched-pairs
signed rank test. (C) Expression of ARG1 in sorted Lineage-HLA-DR-CD11b+CD33+ cells from healthy volunteers
before and 7 days after oral treatment with clarithromycin (CAM) (800 mg/day) (n = 6). Data are presented as the
mean ± SEM. p< 0.001 by the Mann–Whitney U-test.
https://doi.org/10.1371/journal.ppat.1006955.g007
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structural cells [8]. Our study is distinguished from previous reports in that it identified the
unique immunosuppressive cell population mediating these effects in mice, and implicates a
homologous cell population in humans.
Our analyses indicated that the CAM-treated CD11b+Gr-1+ cells were MDSC-like cells.
MDSCs are a population comprised of heterogeneous cell clusters consisting of myeloid pro-
genitor cells and immature myeloid cells, e.g., immature neutrophils [10]. The differences
between granulocytic-MDSCs and mature neutrophils are often debatable [27, 28]. Here, we
confirmed that the CAM-treated CD11b+Gr-1+ cell population includes both CD11b+Ly6-
G+Ly6Clow cells (granulocytic-MDSC-like cells) and CD11b+Ly-6G−Ly-6C+ cells (monocytic-
MDSC-like cells). We cannot estimate the magnitude of the contributions of these two popula-
tions (granulocytic- and monocytic-MDSC-like cells) to the beneficial effects of CAM treat-
ment because we used an anti-Gr-1 antibody (RB6-8C5 clone, anti-Ly-6G and Ly-6C
antibody) to deplete the Gr-1+ cell population. The CAM-treated CD11b+Gr-1+ cell popula-
tion can be discriminated from mature neutrophils in their anti-inflammatory effects, as
mature neutrophils are generally inflammatory in nature. We showed that CD11b+Gr-1+ cells
actively secrete the anti-inflammatory cytokine IL-10 and suppress the production of the
inflammatory cytokines IFN-γ and TNF-α, although selected neutrophils have also been
reported to produce IL-10 [29]. In addition, our results indicating that elastase activity and
MPO activity were lower in CAM-treated CD11b+Gr-1+ cells than in activated neutrophils/
monocytes/macrophages, including LPS-treated CD11b+Gr-1+ cells and thioglycolate-induced
neutrophils, are consistent with the notion that CAM-treated CD11b+Gr-1+ cells are not acti-
vated neutrophils, but MDSC-like cells.
Importantly, our work demonstrated that CAM-treated CD11b+Gr-1+ cells potentiate the
production of IL-10, an anti-inflammatory cytokine that plays a central role in infection by lim-
iting the immune response to pathogens and preventing damage to the host [30]. Many earlier
studies found that IL-10 promotes survival in sepsis and endotoxin shock [31–33], consistent
with our results indicating beneficial effects of IL-10 in LPS-induced shock. IL-10 has been
reported to have detrimental roles in post-influenza pneumococcal pneumonia [34, 35]; how-
ever, another previous study found no significant differences in susceptibility to post-influenza
secondary pneumococcal infection between WT and Il10-/- mice [22]. We did not determine
the detailed mechanisms underlying increased IL-10 levels in the post-influenza pneumococcal
pneumonia model in the present study, but this should be evaluated in further studies.
We also showed that CAM-treated CD11b+Gr-1+ cells distinctly suppressed IFN-γ produc-
tion both in vitro and in vivo, corroborating earlier studies of the 14-membered ring macrolide
erythromycin in a mouse model of influenza virus infection [36]. The significance of sup-
pressed IFN-γ production in LPS-induced endotoxin shock was not evaluated in the present
study; however, IFN-γ has been reported to be detrimental in LPS-endotoxin shock by ham-
pering endotoxin tolerance [37, 38]. Considering these previous reports and our results indi-
cating the partial restoration of IFN-γ production in macrophages co-cultured with CAM-
treated Il10-/- CD11b+Gr-1+ cells (Fig 4C), we speculate that enhanced IL-10-mediated IFN-γ
suppression by CAM would also protect against LPS-induced endotoxin shock. In terms of sig-
nificance, a previous study indicated that IFN-γ production by CD4+ and CD8+ T cells in
response to influenza virus infection enhanced susceptibility to secondary pneumococcal
infection [22]. In addition, accumulating evidence indicates that CD11b+Gr-1+ cells suppress
IFN-γ production by T cells [39, 40] and NK cells [41]. As such, we speculate that the suppres-
sion of IFN-γ production in these cells, as well as macrophages, by CAM treatment would
have protective effects in post-influenza pneumococcal pneumonia. Consistent with this
notion, we confirmed that exogenous administration of recombinant IFN-γ partially reversed
the survival benefit in post-influenza pneumococcal pneumonia model mice. We also observed
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slightly greater survival in CAM-treated Ifng-/- mice than in vehicle-treated Ifng-/- mice and
CAM-treated WT mice. These results suggest that the protective effects of CAM in this model
at least partially depend on suppression of IFN-γ production. We speculate that, in addition to
IFN-γ suppression, other mechanisms, such as increased IL-10, contribute to the protective
effects of CAM in this model.
Furthermore, we found that the STAT3/Bv8 axis is actively involved in the mechanism
underlying CAM-induced CD11b+Gr-1+ cell expansion. Bv8 induces CD11b+Gr-1+ cells in an
autocrine and paracrine STAT3-dependent manner [24], and regulates CD11b+Gr-1+ cell-
dependent tumor angiogenesis [42]. A Bv8 antagonist was found to inhibit angiogenesis and
myeloid cell infiltration in mouse models of glioblastoma and pancreatic cancer [43]. These
studies, in combination with our study, suggest that the STAT3/Bv8 axis is essential to myeloid
cell recruitment, including that of CD11b+Gr-1+ cells. In addition, because STAT3 plays a cru-
cial role in the IL-10-mediated anti-inflammatory response [44], and considering our results
for IL-10 induction from CAM-treated CD11b+Gr-1+ cells, it is likely that the expanded
CD11b+Gr-1+ cell population mediates its immunomodulatory effects via STAT3-dependent
IL-10 production.
Previous studies have clearly demonstrated that 14- and 15-membered, but not 16-mem-
bered macrolide antibiotics, can decrease pro-inflammatory cytokine and chemokine secretion
[8, 19, 20]. Similarly, we observed expansion of CD11b+Gr-1+ cells following treatment with
14- and 15-membered, but not 16-membered macrolide antibiotics, suggesting that the degree
of CD11b+Gr-1+ cell expansion is correlated with their immunomodulatory properties. Thus,
macrolide-treated CD11b+Gr-1+ cells might be a good biological marker for evaluating the
potency of their immunomodulatory properties.
Oral administration of 25–100 mg/kg CAM in mice is comparable to clinically achievable
levels in humans [45]. As the area under the curve (AUC) was more than 2-fold higher for
intraperitoneal administration of 10 mg/kg CAM than for oral administration of 10 mg/kg
CAM (personal communication), we believe that the intraperitoneal administration of CAM
at 100 mg/kg in the present study is clinically relevant for humans.
The overuse of macrolide antibiotics could result in the evolution of macrolide-resistant
organisms. To address this concern, immunomodulatory macrolides lacking antimicrobial
effects, e.g., EM900 and EM703, have been in development [46, 47]. The presence of immuno-
suppressive CD11b+Gr-1+ cells can be a good surrogate marker to measure the immunomodu-
latory effects of these types of drugs in early development.
Finally, we tried to identify the human immunosuppressive MDSC population that corre-
sponds to murine CD11b+Gr-1+ cells. Exact human MDSC surface markers are yet to be iden-
tified, partly owing to the extensive heterogeneity in the human MDSC population [11].
However, based on previous studies [11], we identified Lineage-HLA-DR-CD11b+CD33+ cells
as a major human MDSC population. In addition, we observed upregulation of arginase-1
mRNA in the human MDSC population after oral administration of CAM, indicating that
CAM likely expands immunosuppressive MDSC-like cells in humans. In the present study,
peripheral blood was used to assess CAM-treated human MDSCs, but these effects could be
evaluated with much greater clarity in lung or spleen cell populations, as in the model mice.
In the present study, we used an anti-Gr-1 antibody (RB6-8C5 clone, anti-Ly-6G and Ly-
6C antibody) to deplete the Gr-1+ cell population, resulting in depletion of both monocytic-
and granulocytic-MDSC-like cell populations. This may not be a good approach for the deple-
tion of MDSC-like cells owing to the lack of selectivity, i.e., myeloid cells such as neutrophils
and monocytes/macrophages can also be depleted by treatment with the anti-Gr-1 antibody.
Although several parameters have been suggested for distinguishing granulocytic-MDSCs from
neutrophils [14], they are insufficient [48]. Further investigations are needed to better
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differentiate these cells. A working hypothesis for the mechanism underlying CAM-mediated
expansion of the CD11b+Gr-1+ cell population is summarized in S15 Fig. In this system, CAM
expands the CD11b+Gr-1+ cell population in a STAT3/Bv8-dependent manner. The anti-
inflammatory effects of these cells, including increased IL-10 and decreased IFN-γ, are sufficient
to protect mice from death by LPS-induced shock and post-influenza pneumococcal
pneumonia.
In conclusion, we identified a novel mechanism underlying CAM-mediated expansion of
the immunosuppressive CD11b+Gr-1+ cell population, sufficient to attenuate LPS-induced
lethal shock and post-influenza pneumococcal infection. Considering that the immunosup-
pressive effects of CD11b+Gr-1+ cells may also ameliorate various inflammatory diseases,
our findings provide a new strategy for the treatment of inflammatory diseases and the devel-
opment of new classes of macrolides and novel drugs. Further detailed studies would con-




Male WT C57BL/6J mice (8–10 weeks old) were purchased from CLEA Japan, Inc. (Tokyo,
Japan). Il10−/− mice and Ccl2-/- mice were purchased from Jackson Laboratory (Bar Harbor,
ME, USA). Il17a-/- and Ifng-/- mice were kindly provided by Prof. Yoichiro Iwakura (Tokyo
University of Science, Noda, Japan). Ifnar1-/- mice were kindly provided by Prof. Shigekazu
Nagata (Kyoto University, Kyoto, Japan) [48, 49].
Stat3flox/flox mice and Myd88-/- mice were purchased from Oriental BioService, Inc. (Kyoto,
Japan) Mx-1-Cre mice were kindly provided by the Mouse Genetics Cologne Foundation in
Germany. Stat3ΔMx1 mice were generated by mating Stat3flox/flox mice with Mx-1-Cre mice. To
remove the floxed Stat3 allele, 8-week-old Stat3ΔMx1 mice were intraperitoneally injected with
250 μg of polyinosinic-polycytidylic acid ([Poly(I:C)]; Sigma-Aldrich, St. Louis, MO, USA)
three times every other day. Littermate Stat3flox/flox mice served as controls. Germ-free mice
were purchased from CLEA Japan, Inc., and were kept in the germ-free facility at Keio Uni-
versity School of Medicine. Other mice were housed under specific pathogen-free (SPF)
conditions.
Ethics statement
The present study was performed in strict accordance with the recommendations of the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal
experiments were approved by the Animal Care and Use Committee at the Keio University
School of Medicine (Protocol No. 12110). The human study was approved by the Ethics Com-
mittee of Keio Center for Clinical Research in November 2012 (Protocol No. 20120250). All
participants of the study (i.e., blood donors) were informed about the risks of participation in
the study and written consent was obtained from all of them. All participants were adults and
non-minors.
Preparation and injection of clarithromycin and other antibiotics
Clarithromycin (CAM) was kindly provided by Taisho Toyama Pharmaceutical Co., Ltd.
(Tokyo, Japan), and diluted with PBS containing 5% gum arabic. The CAM or vehicle solution
(5% gum arabic in PBS) was intraperitoneally injected at 100 mg/kg daily throughout the
course of the experiment. In oral administration experiments, the CAM and vehicle solutions
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were administered at 100 mg/kg by gavage daily for 14 days. The dose of CAM was determined
based on preliminary experiments summarized in S1 Fig and previous reports [45, 50, 51]. Azi-
thromycin (Sigma-Aldrich), josamycin (Sigma-Aldrich), and ampicillin (Sigma-Aldrich) were
dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at 10 mg/mL and further diluted in
sterile PBS. Antibiotics were administered in vivo at 100 mg/kg, 200 mg/kg, and 100 mg/kg,
based on previous reports [51–54].
Flow cytometry and sorting
In mouse studies, single-cell suspensions were prepared for flow cytometry as follows; spleens
and lungs were cut into small fragments and digested for 45 min at 37˚C with RPMI 1640 con-
taining 0.05 mg/mL Liberase (Roche Diagnostics, Basel, Switzerland) and 250 U/mL DNAse I
(Worthington Biochemical Corporation, Lakewood, NJ, USA). Single cells were washed with
fluorescence activated cell sorting (FACS) buffer (2% fetal calf serum [FCS] and 1 mg/mL sodium
azide in PBS) and incubated with an anti-CD16/CD32 monoclonal antibody (eBioscience, San
Diego, CA, USA) for 10 min followed by staining with the following antibody conjugates for 20
min: PE-Cy7-CD45 (30-F11; BioLegend, San Diego, CA, USA), APC-Cy7-CD45 (30-F11; BD
Biosciences, Franklin Lakes, NJ, USA), PerCP-Cy5.5-CD45 (30-F11; BD Biosciences), PE-Cy7-
CD3 (17A2; BioLegend), PerCP-Cy5.5-CD4 (GK1.5; BioLegend), APC-Cy7-CD8a (53–6.7;
BioLegend), APC-TCR-γδT (B1; BioLegend), PE-NK1.1 (PK136; BioLegend), APC-Gr-1 (RB6-
8C5; BioLegend), FITC-CD11b (M1/70; BioLegend), APC/Cy7-Ly-6G (1A8; BioLegend), PerCP/
Cy5.5-Ly-6C (HK1.4; BioLegend), PE-CD244.2 (2B4 B6; eBioscience), PE-CTLA-4 (BioLegend),
PE-PD1 (eBioscience), PE-PDL1 (eBioscience), PE-CXCR2 (BioLegend), PE-CXCR4 (eBio-
science), PE-CD80 (BioLegend), PE-CD115 (eBioscience), and PE-CX3CR1 (R&D Systems,
Minneapolis, MN, USA). The cells were then washed twice and subsequently stained with
PE-Texas Red propidium iodide (PI; BD Biosciences).
The antibody conjugates PE-CD33 (HIM3-4; BD Biosciences), Alexa700-CD11b (CR3A;
BioLegend), PE/Cy7-HLA-DR (BioLegend), FITC-Lineage (CD3, CD19, CD56) (eBioscience),
and APC/Cy7-CD45 (HI30; BioLegend) were used for human cell analyses. The cells were
washed twice and stained with PE-Texas Red PI (BD Biosciences).
Stained cells were processed by flow cytometry using a BD FACS Aria II system (BD Biosci-
ences) or MoFlo XDP (Beckman Coulter, Brea, CA, USA) and the data were analyzed using
FlowJo 7.6.2 (Tree Star, Inc., Ashland, OR, USA).
Immunofluorescence
Lung tissue was fixed with 4% paraformaldehyde and embedded in paraffin. The lung sections
were deparaffinized in xylene and rehydrated in a graded ethanol series, and antigen retrieval
was performed by heating sodium citrate buffer at 95˚C for 20 min. Non-serum protein block
(Dako) was applied for 30 min. Slides were then stained with rat anti-Gr-1 primary antibody
(RB6-8C5; R&D Systems) or rabbit anti-arginase-1 primary antibody (ABS535; Merck, Kenil-
worth, NJ, USA) followed by Alexa Fluor 488- or Alexa Fluor 555-coupled secondary antibody,
respectively (Invitrogen, Carlsbad, CA, USA). Sections were counterstained with DAPI (Vec-
tor Labs) and analyzed using an Axio Imager (Zeiss, Oberkochen, Germany).
In vivo antibody labeling
After mice were anesthetized by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (100
mg/kg), an APC-Cy7-CD45 antibody conjugate (0.4 μg/2 μL diluted in 100 μL of PBS) was ad-
ministered 5 min before euthanasia together with heparin (10 IU/g). After 5 min, mice were exsan-
guinated and intratracheally injected with a PerCPCy5.5-CD45 antibody conjugate (0.4 μg/2 μL
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diluted in 100 μL of PBS). After an additional 5 min, the lungs were harvested and a lung single cell
suspension was prepared, followed by staining with a PE-Cy7-CD45 antibody conjugate ex vivo.
Microarray analysis
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to
the manufacturer’s protocol. The isolated RNA was quantified, and quality was assessed using
an Agilent 2100 BioAnalyzer with the RNA Nano Chip (Agilent, Santa Clara, CA, USA). Then,
2 μg of total RNA was used to generate single-stranded antisense cDNA using the Ovation Bio-
tin System (NuGEN Technologies, San Carlos, CA, USA) according to the manufacturer’s
instructions. Labeled targets were hybridized to Affymetrix MOE430 2.0 GeneChip microar-
rays (Affymetrix) for 16 h at 45˚C. The arrays were washed and scanned according to standard
Affymetrix protocols. GeneSpring 12.0 (Silicon Genetics, Redwood City, CA, USA) was used
for data analysis. Microarray data sets have been deposited in the National Center for Biotech-
nology Information (NCBI) Gene Expression Omnibus under accession number GSE81241.
Arginase activity
Splenic CD11b+Gr-1+ cells sorted from CAM- or vehicle-treated mice were lysed in 50 μL of
RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with Halt Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail 2 (Sigma-
Aldrich). The lysate was collected by centrifugation at 14,000 × g at 4˚C for 15 min and 100 μL
of ddH2O was added. Arginase activity was determined using the QuantiChrom Arginase
Assay Kit (BioAssay Systems, Hayward, CA, USA) following the manufacturer’s instructions.
Nitric oxide measurement
The NO concentration in spleen extracts was determined using the Quantichrom Nitric Oxide
Assay Kit (BioAssay Systems) according to the manufacturer’s instructions.
T cell proliferation assay
CD3+ T cells were isolated from splenocytes by negative selection, using a magnetic cell sorting
system (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). Sorted cells were washed and
resuspended in 5 mL of PBS/0.1% bovine serum albumin (BSA). T cell proliferation assays
were performed using the CellTrace CFSE Cell Proliferation Kit (Thermo Fisher Scientific)
according to the manufacturer’s instructions. Briefly, the sorted CD3+ T cells were incubated
with CFSE for 20 min, washed, and then stimulated with anti-CD3 antibody (5 μg/mL) (BioLe-
gend) and anti-CD28 antibody (1 μg/mL) (BioLegend). The CFSE-labeled CD3+ T cells were
then co-cultured with sorted splenic CAM-treated or vehicle-treated CD11b+Gr-1+ cells for 3
days prior to fluorescence intensity analysis by flow cytometry.
Elastase activity assay
The Neutrophil Elastase Activity Assay Kit (Cayman, Ann Arbor, MI, USA) was used to mea-
sure elastase activity according to the manufacturer’s instructions.
Myeloperoxidase activity assay
The Myeloperoxidase (MPO) Activity Assay Kit (Colorimetric) (ab105136; Abcam, Cam-
bridge, UK) was used to measure MPO activity according to the manufacturer’s instructions.
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Phagocytic activity assay
The Phagocytosis Activity Assay Kit (IgG FITC) (Cayman) was used to measure phagocytic
activity according to the manufacturer’s instructions.
Preparation of various types of CD11b+Gr-1+ cells, neutrophils, and
monocytes
To prepare LPS-treated CD11b+Gr-1+ cells, mice were intraperitonially injected with LPS (50
mg/kg), and splenic CD11b+Gr-1+ cells 12 h after LPS treatment were sorted using anti-Gr-1
magnetic beads. To prepare thioglycolate-induced neutrophils, mice were intraperitoneally
injected with 3% thioglycolate in 2 mL of PBS. Peritoneal neutrophils were recovered 4 h after
the injection. For isolation of peripheral neutrophils, the Cell-based Assay Neutrophil Isolation
Histopaque kit was used according to the manufacturer’s instructions (Cayman). To prepare
monocytes, Monocyte Isolation Kit (BM) was used according to the manufacturer’s instruc-
tions (Miltenyi Biotec).
Culture of murine bone marrow-derived macrophages
Bone marrow cells were harvested from 8–10-week-old-male C57BL/6J mice by flushing the
femur and tibia with RPMI 1640 medium. Recovered cells were then cultured in bone marrow
cell medium (20% FCS, 30% L-cell supernatant, 2 mM L-glutamine, 1% penicillin/streptomy-
cin, 0.25 μg/mL amphotericin B in RPMI 1640). Fresh bone marrow cell medium was added
on day 3. On day 6, adherent cells were replated in RPMI 1640 medium supplemented with
10% FCS, 2 mM L-glutamine, and 1% penicillin/streptomycin for use as BMDMs. On day 7,
the medium was removed and BMDMs were cultured with or without CD11b+Gr-1+ cells
(either CAM-treated or vehicle-treated) for 1 h, followed by stimulation with LPS for 12 h.
Enzyme-linked immunosorbent assay
TNF-α, IFN-γ, and IL-10 levels were measured using a DuoSet ELISA Kit (R&D Systems)
according to the manufacturer’s instructions.
Lipopolysaccharide-induced endotoxin shock mice model
Mice received a single intraperitoneal (i.p.) injection of 50 mg/kg LPS (Escherichia coli O111:
B5; Sigma-Aldrich). For CAM pre-treatment, mice were intraperitoneally injected with CAM
(100 mg/kg) once daily for three consecutive days, followed by LPS challenge the day after the
last injection of CAM.
For the pharmacological depletion of Gr-1+ cells, mice received an i.p. injection of an anti-
Gr-1 antibody (250 μg/mouse) (clone RB6-8C5; BioLegend) or isotype control antibody 24 h
before LPS challenge or 1 h before starting CAM treatment (i.e., 73 h before LPS challenge).
The antibody dose was determined according to our previous study [55].
For adoptive transfer experiments, splenic CD11b+Gr-1+ cells (1 × 106/mouse) in 0.1 mL of
PBS sorted from CAM- or vehicle-treated mice were intravenously transferred into mice by
tail vein injection.
Influenza virus and secondary Streptococcus pneumoniae infection in mice
Influenza virus A/H1N1/PR8/34 (PR8) was kindly provided by Dr. Hideki Hasegawa
(National Institute of Infectious Diseases, Tokyo, Japan) [56]. The PR8 virus titer was mea-
sured by a plaque forming assay using Madin-Darby canine kidney (MDCK) cells (CCL-34;
American Type Culture Collection).
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S. pneumoniae was kindly provided by Dr. Kimiko Ubukata (Keio University, Tokyo,
Japan). The strain was clinically isolated (serotype 3) and was both penicillin- and macrolide-
resistant, harboring penicillin resistance (penicillin binding protein [pbp1a, pbp2x, and
pbp2b]) and macrolide resistance (mefA and ermB) genes. Detailed drug susceptibility testing
of the strain is shown in S1 Table. The minimum inhibitory concentration (MIC) of Penicillin
G was 1, and therefore the strain was identified as clinically penicillin-intermediate S. pneumo-
niae (PISP) according to Clinical and Laboratory Standards Institute (CLSI) definition M100
S26:2016.
To establish the post-influenza secondary S. pneumoniae infection mouse model, mice were
intranasally inoculated with five plaque-forming units (PFUs) of PR8. Seven days after PR8
infection, the mice were intranasally infected with 1 × 104 colony-forming units (CFUs) of S.
pneumoniae suspended in 50 μL of PBS. Mice were then intraperitoneally injected with CAM
(100 mg/kg) diluted in PBS with 5% gum arabic or vehicle daily starting from 1 h after pneu-
mococcal infection throughout the course of the experiment. Mice were monitored for survival
for up to 5 days after pneumococcal infection. A 7-day interval between influenza infection
and subsequent S. pneumoniae inoculation was used as a lethal model in the present study,
based on previous studies [21, 57].
For IFN-γ administration, mice were intranasally inoculated with 16 μg/kg recombinant
IFN-γ (PeproTech) or vehicle at 30 min and 24 h after pneumococcal infection. The dose of
recombinant IFN-γ was determined according to a previous report [58] and survival was mon-
itored for 7 days.
Bronchoalveolar lavage
Bronchoalveolar lavage fluid (BALF) was collected with 0.7 mL of saline, and total cell counts
were determined [59].
Bacterial load
Whole left lungs were harvested and homogenized with 1 mL of sterile PBS with 0.1% Triton
X and serially diluted with sterile PBS. Equal volumes of each dilution of the lung homogenates
and blood were applied to trypticase soy agar (TSA) plates containing 5% sheep blood (BD
Trypticase Soy Agar II with 5% Sheep Blood; BD Diagnostics) and incubated overnight at
37˚C. After overnight incubation, bacterial colonies were counted and expressed as CFUs per
mL of solution.
Histological analysis
Lung specimens harvested 18 h after pneumococcal infection were fixed with 4% paraformal-
dehyde. After dehydration and embedding in paraffin, 3-μm sections were stained with hema-
toxylin and eosin (H&E).
Protein extraction from whole lung tissues and immunoblotting
Whole lung tissues were homogenized using a Dounce tissue homogenizer on ice in RIPA
Lysis and Extraction Buffer (Thermo Fisher Scientific). Homogenates were centrifuged at
12,000 × g at 4˚C for 20 min, and the supernatants were collected and stored at −80˚C until
use for protein analysis. Bicinchoninic acid (BCA) protein assays (Thermo Fisher Scientific)
were used to measure the total protein concentration in lung homogenates.
Equal amounts (15–30 μg) of cell lysates were fractionated by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (Bio-Rad Laboratories), and the proteins were transferred to a
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polyvinylidene fluoride membrane (Bio-Rad Laboratories). After overnight incubation with
antibodies against prok2 (Millipore, Billerica, MA, USA), STAT3, or p-STAT3 (both from Cell
Signaling Technology, Danvers, MA, USA), the membrane was counterstained with horserad-
ish peroxidase-conjugated rabbit IgG antibody and visualized with enhanced chemilumines-
cence detection reagents (GE Healthcare). Images were analyzed using ImageJ 1.45v (National
Institutes of Health, Bethesda, MD, USA).
Analysis of anti-Bv8/Prok2 antibody treatment
The anti-Bv8 antibody was kindly provided by Genentech. Mice were intraperitoneally
injected with the anti-Bv8 antibody (5 mg/kg) or control IgG at 4 days and 1 day before CAM
treatment and once daily for three consecutive days during CAM treatment.
Quantitative real-time polymerase chain reaction
Total RNA was isolated from the lung or spleen using the RNeasy Mini Kit according to the
manufacturer’s instructions (QIAGEN). Total RNA was reverse-transcribed using the High-
Capacity RNA-to-cDNA cDNA Kit (Life Technologies). Real-time quantitative polymerase
chain reaction (PCR) was performed using SYBR Green chemistry on a 7500 Fast Real-Time
PCR system (Applied Biosystems). The primer sequences for each target gene are provided in
S2 Table.
Purification of human peripheral blood cells
Peripheral blood cells were isolated from healthy subjects. Red blood cells (RBCs) were
removed from 40 mL of heparinized peripheral blood using Dextran T-500 (Pfizer). After
removal any remaining RBC using ammonium-chloride-potassium (ACK) lysis buffer (Lonza,
Basel, Switzerland), peripheral cells were stained with antibodies described above.
Statistical analysis
Data are expressed as the mean ± SEM and analyzed using the Mann–Whitney-U-test, Wil-
coxon matched-pairs signed rank test, or ANOVA, followed by Tukey’s tests for multiple com-
parisons. Log-rank tests were performed for survival studies. p< 0.05 was considered
statistically significant.
Supporting information
S1 Table. Drug susceptibility of the S. pneumoniae strain used in the present study. Mini-
mum inhibitory concentrations of indicated antimicrobial agents are shown.
(DOCX)
S2 Table. Primer sequences used in quantitative real-time PCR. Primer sequences of Arg1,
Il10, Prok2, and ARG1 are shown.
(DOCX)
S1 Fig. Clarithromycin expands CD11b+Gr-1+ cells in a dose- and time-dependent man-
ner. (A and B) Mice were intraperitoneally injected with CAM once a day with doses of 0
(vehicle control), 20 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg for three consecutive days.
On the day after the last injection, CD11b+Gr-1+ cells in the spleen (A) and lungs (B) were ana-
lyzed by flow cytometry (n = 4 in each condition). (C and D) Mice were intraperitoneally
injected with either CAM (100 mg/kg) or vehicle daily, starting from day 0 through the day
before the indicated days. CD11b+Gr-1+ cells in the spleen (C) and lungs (D) were then
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analyzed by flow cytometry (n = 4 in each condition). Data are presented as the mean ± SEM.
p< 0.05; p< 0.01; p< 0.001 by the Mann–Whitney U-tests.
(TIF)
S2 Fig. Immunofluorescence staining and FACS analysis of Gr-1+ cells in lungs. (A and B)
Gr-1 immunofluorescence staining in the lungs of mice treated with (A) vehicle or (B) CAM
daily for three consecutive days (n = 4 per group). Scale bar, 100 μm. (C) Two-parameter dot
plots of CD11b+Gr-1+ cells in lungs sorted from mice intraperitoneally treated with vehicle or
CAM daily for three consecutive days. The mice were intravenously injected with an APC--
Cy7-CD45 antibody conjugate for 5 min, sacrificed, and intratracheally injected with a
PerCP-Cy5.5-CD45 antibody conjugate for 5 min. Next, a lung single cell suspension was pre-
pared and stained with a PE-Cy7-CD45 antibody conjugate.
(TIF)
S3 Fig. Arginase-1 mRNA expression after intraperitoneal and oral CAM administration.
(A) Mice were intraperitoneally administered CAM daily for three consecutive days. On the
day after the last administration, splenic CD11b+Gr-1+ cells were sorted and arginase-1
mRNA (Arg1) expression was measured by quantitative real-time PCR. (B) Mice were orally
administered CAM daily for seven consecutive days. The day after the last administration,
splenic CD11b+Gr-1+ cells were sorted and Arg1 expression was measured by quantitative
real-time PCR (n = 3 in each group). Data are presented as the mean ± SEM.
(TIF)
S4 Fig. Elastase activity, MPO activity, and phagocytic activity in CAM-treated CD11b+Gr-1+
cells. (A) Elastase activity in vehicle-treated CD11b+Gr-1+ cells (a), CAM-treated CD11b+Gr-1+
cells (b), LPS-treated CD11b+Gr-1+ cells (c), thioglycolate-induced neutrophils (d), and isolated
peripheral neutrophils (e) was measured using the commercially available Neutrophil Elastase
Activity Assay Kit (n = 3). (B) MPO activity in indicated cells was measured using the commer-
cially available MPO Activity Assay Kit (n = 3). (C) Phagocytic activity in indicated cells was
measured using the commercially available Phagocytosis Activity Assay Kit (n = 3). f: Isolated
monocytes.
(TIF)
S5 Fig. CD3+ T cell proliferation assay after co-culture with vehicle-treated or CAM-
treated CD11b+Gr-1+ cells. CD3+ T cell proliferation was measured by the carboxyfluorescein
succinimidyl ester (CFSE) method when co-cultured with equal numbers of vehicle-treated or
CAM-treated CD11b+Gr-1+ cells (1 × 105 cells) from the spleen. (n = 4 per group). A represen-
tative histogram is shown.
(TIF)
S6 Fig. Surface expression of various immune markers in CAM-treated CD11b+Gr-1+ cells.
Various surface markers, including CD244, CTLA-4, PD-1, PD-L1, CXCR2, CXCR4, CD80,
CD115, and CX3CR1, on splenic CD11b+Gr-1+ cells were measured by flow cytometry (n = 4
per group).
(TIF)
S7 Fig. Potency of CAM and other macrolides in the expansion of CD11b+Gr-1+ cells. (A)
Mice were intraperitoneally injected with vehicle, clarithromycin (CAM) (100 mg/kg), azithro-
mycin (AZM) (100 mg/kg), or josamycin (JOS) (200 mg/kg) daily for three consecutive days.
Representative two-parameter dot plots of CD11b+Gr-1+ cells in the spleen (upper panel) and
lungs (lower panel) are shown. (B and C) Quantification of splenic (B) and lung (C) CD11b+Gr-
1+ cells obtained from vehicle-, CAM-, AZM-, and JOS-treated mice are shown (n = 8–9 in each
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group). N.S., not significant. p< 0.01; p< 0.001; #p< 0.05; ###p< 0.001 by a one-way
ANOVA with Tukey’s multiple comparison tests.
(TIF)
S8 Fig. Experimental schema for depletion of the Gr-1+ cell population. (A) Pharmacologi-
cal depletion of the Gr-1+ cell population using an anti-Gr-1 antibody was performed 24 h
before LPS challenge (results summarized in Fig 3H). (B) Pharmacological depletion of the
Gr-1+ cell population using an anti-Gr-1 antibody was performed 1 h before initiation of
CAM treatment (i.e., 73 h before LPS challenge) (results summarized in Fig 3I).
(TIF)
S9 Fig. Adoptive transfer of CAM- and vehicle-treated CD11b+Gr-1+ cells, and PBS control
injection in LPS endotoxin shock. CAM- and vehicle-treated CD11b+Gr-1+ cells (1 × 106
cells) from the spleen and PBS control were intravenously injected via tail vein in mice sub-
jected to LPS endotoxin shock. (n = 15–16 per group). N.S.; not significant by the log-rank
test.
(TIF)
S10 Fig. Expansion of CD11+Gr-1+ cells is independent of IL-10. WT and Il10-/- mice were
intraperitoneally injected with vehicle or clarithromycin (CAM) (100 mg/kg) daily for three
consecutive days. On the day after the last injection, single splenic and lung cell suspensions
were subjected to flow cytometry. Representative two-parameter dot plots of CD11b+Gr-1+
cells from the spleen are shown (n = 3 in each condition).
(TIF)
S11 Fig. Josamycin does not improve survival in post-influenza pneumococcal pneumonia.
Survival rate of mice with post-influenza pneumococcal pneumonia treated with vehicle, clari-
thromycin (CAM) (100 mg/kg), or josamycin (JOS) (200 mg/kg) (n = 15–16 per group). N.S.;
not significant. p< 0.05 by the log-rank test.
(TIF)
S12 Fig. Role of type I IFN in post-influenza pneumococcal pneumonia. Survival rate of
vehicle- or CAM-treated (100 mg/kg daily for consecutive days) WT and Ifnar1-/- mice in
post-influenza pneumococcal pneumonia mice (n = 4–16 per group).
(TIF)
S13 Fig. CD11+Gr-1+ cell expansion is independent of IL-17, CCL2, MyD88, and CXCR4. (A–
C) WT, Il17a-/- mice (A), Ccl2-/- mice (B), or Myd88-/- mice (C) were intraperitoneally injected
with vehicle or clarithromycin (CAM) (100 mg/kg) daily for three consecutive days. On the day
after the last injection, single splenic cell suspensions were subjected to flow cytometry. Represen-
tative two-parameter dot plots of CD11b+Gr-1+ cells from the spleen are shown (n = 4 in each
condition). (D) Mice were intraperitoneally treated with a CXCR4 antagonist (AMD3100, Milli-
pore) (5 mg/kg) or vehicle. One hour after injection, mice were intraperitoneally injected with
vehicle or CAM (100 mg/kg) daily for three consecutive days, as described in (A–C). Representa-
tive two-parameter dot plots of splenic CD11b+Gr-1+ cells are shown (n = 4 in each condition).
(TIF)
S14 Fig. Gut commensal microbiota may be involved CD11b+Gr-1+ cell expansion. (A and
B) Representative two-parameter dot plots of CD11b+Gr-1+ cells in the spleen (A) and lungs
(B) of mice treated with vehicle or CAM (100 mg/day) for three consecutive days in specific
pathogen-free (SPF) mice and germ-free mice (n = 3 per group). (C) Percentage of
CD11b+Gr-1+ cells in the spleen and lungs of mice treated with vehicle or CAM (100 mg/day)
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for three consecutive days in SPF mice and germ-free mice. p< 0.05 (n = 3 per group). (D
and E) Quantification of CD11b+Gr-1+ cells in the spleen (D) and lungs (E) of SPF and germ-
free mice treated with vehicle or CAM (100 mg/day) treatment for three consecutive days.
p< 0.05 (n = 3 per group).
(TIF)
S15 Fig. Schematic illustration of the immunosuppressive effects of CAM-treated
CD11b+Gr-1+ cells in the present study. CAM expands the CD11b+Gr-1+ cell population
depending on the STAT3/Bv8 signaling pathway. CAM-treated CD11b+Gr-1+ cells subse-
quently protect mice against LPS-induced shock mostly via increased IL-10, and protect mice
from post-influenza pneumococcal pneumonia, mainly via decreased IFN-γ.
(TIF)
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